Allied Market Research

2024

U.s. Cardiac Troponin Market

U.S. Cardiac Troponin Market Size, Share, Competitive Landscape and Trend Analysis Report by Type, by Application and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Cardiac markers are used as traceable substances while diagnosing patients with chest pain and suspected acute coronary syndrome (ACS). Cardiac troponins are one of the cardiac biomarkers or diagnostic markers centralized to myocardial infarction or heart muscle cell death diagnosis. Troponin is found in skeletal muscle and cardiac muscle of human body, thus increased level of the cardiac troponin circulating in the blood represents the susceptibility of myocardial infarction.

The growth of the U.S. cardiac troponin market is driven by increase in demand for cardiac biomarkers for cardiovascular disease diagnosis, rise in incidence of acute coronary syndrome (ACS), advancements in the cardiac biomarkers, and growth in demand for point-of-care cardiac testing kits. High specificity and sensitivity of these markers to detect any cardiac disorders and development of new products by the key market players contribute towards the market growth.

However, factors such as limited reimbursements and lack of precision while collecting sample impede the market growth. The development of multi-assay biomarkers and increase in awareness of cardiac troponin biomarkers in developing countries are expected to supplement the market growth in the near future.

The U.S. cardiac troponin market is segmented on the basis of product, application, and end user. Based on product, the market is categorized into cTn T, cTn I, and TnC. Applications covered in the study include acute coronary syndrome, myocardial infarction, congestive heart failure, and others. By end user, the market is bifurcated into laboratory testing and point of care testing.

The major players operating in this market include Abbott Diagnostics, Inc., F. Hoffmann-La Roche Ltd, bioMrieux SA, BG Medicine, Inc., Ortho-Clinical Diagnostics, Inc., Singulex, Inc., Alere, Inc., Siemens Healthcare Diagnostics, Inc., Beckman Coulter, Inc., and LifeSign LLC.

Key Benefits

  • The study provides an in-depth analysis of the U.S. cardiac troponin market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global biologic response modifiers market which helps to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the U.S. cardiac troponin market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the U.S. cardiac troponin market.

U.S. Cardiac Troponin Market Report Highlights

Aspects Details
icon_5
By Type
  • Troponin I (cTnI)
  • Troponin T (cTnT)
icon_6
By Application
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Others Applications
icon_7
By End User
  • Laboratory Testing
  • Point-of-care Testing
icon_8
By Region
  • North America  (U.S.)
icon_9
Key Market Players

F. Hoffmann-La Roche Ltd., Alere, Inc., Siemens Healthcare Diagnostics, Inc., bioMrieux SA, LifeSign LLC, Ortho-Clinical Diagnostics, Inc., Beckman Coulter, Inc., Singulex, Inc., Abbott Diagnostics, Inc., BG Medicine, Inc.

Loading Table Of Content...

U.S. Cardiac Troponin Market

Global Opportunity Analysis and Industry Forecast, 2023-2032